<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469661</url>
  </required_header>
  <id_info>
    <org_study_id>FCR-PTI-2017-01</org_study_id>
    <nct_id>NCT03469661</nct_id>
  </id_info>
  <brief_title>Differential Diagnostic of Immune ThrombocytoPenia (ITP) and Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Differential Diagnostic of ITP and MDS: a Prospective Study by Next-Generation Flow Cytometry and Cytomorphological Approaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion CRIS de Investigación para Vencer el Cáncer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion CRIS de Investigación para Vencer el Cáncer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Current diagnostic criteria for Immune ThrombocytoPenia (ITP) are mainly based on the&#xD;
      presence of low numbers of platelets, excluding other multiple causes of thrombocytopenia,&#xD;
      including immunodeficiencies, constitutional or acquired thrombocytopenia, hypersplenism and&#xD;
      clonal hematological disorders such as MDS, disorders lymphoproliferative and acute myeloid&#xD;
      leukemia (AML), among others. The analysis complementary tests for the diagnosis of ITP&#xD;
      include studies basic systematic hematology, together with autoimmune assays and&#xD;
      microbiological tests, while the evaluation of bone marrow is limited to elderly patients&#xD;
      and/or patients resistant to treatment. Previous research has described the development of&#xD;
      Myelodysplastic Syndrome (MDS) in patients with a previous diagnosis of ITP, and even the&#xD;
      presence of MDS associated with genetic background. Therefore, it is conceivable fact that a&#xD;
      percentage of cases with clinical signs of ITP in the moment of appearance may actually&#xD;
      correspond to the first stages of MDS development in which bone marrow cells are not&#xD;
      systematically evaluated in the initial presentation.&#xD;
&#xD;
      The anomalous immunophenotypic patterns between multiple compartments of bone marrow cells&#xD;
      and peripherally blood (PB) platelets have been characterized through flow cytometry. The&#xD;
      flow cytometry currently represents an important complementary tool for diagnosis of MDS that&#xD;
      has shown great effectiveness and applicability in the differential diagnosis of non-clonal&#xD;
      cytopenias against early MDS and for the detection of stages prior to MDS. Besides, the flow&#xD;
      cytometry has made it possible to detect the presence of coexisting features related to MDS&#xD;
      in patients with other malignancies hematologic conditions such as multiple myeloma, AML, and&#xD;
      lymphocytic leukemia chronic. Therefore, the immunophenotypic analysis of the cells of the&#xD;
      bone marrow of patients with ITP at the time of appearance would help to identify the cases&#xD;
      that underlie clonal hematopoiesis MDS type. In the present study it is planned a broad&#xD;
      characterization immunophenotyping of multiple compartments of bone marrow cells and PB&#xD;
      platelets from patients with recently diagnosed ITP and investigate their morphological&#xD;
      antecedents, in order to identify those patients who show compatible clonal hematopoietic&#xD;
      patterns with MDS evident (or at risk of development), as candidates to receive most&#xD;
      appropriate therapeutic methods.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Actual">April 19, 2021</completion_date>
  <primary_completion_date type="Actual">April 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Morphological profile</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone marrow cell compartment profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphological profile</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood platelets profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>Baseline</time_frame>
    <description>Bone marrow cell compartment profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunological profile</measure>
    <time_frame>Baseline</time_frame>
    <description>Peripheral blood platelets profiles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunophenotypic abnormalities</measure>
    <time_frame>Baseline</time_frame>
    <description>Evaluation of abnormal immunophenotypic profiles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morphological abnormalities</measure>
    <time_frame>Baseline</time_frame>
    <description>Evaluation of abnormal morphological profiles.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">63</enrollment>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Immune Thrombocytopenia Diagnosis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Myelodysplastic Syndrome Diagnosis</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Given a diagnosis of ITP or low-risk MDS, EDTA-anticoagulated bone marrow and peripheral&#xD;
      blood aspirates will be obtained per case. A biopsy sample and two unstained blood smears&#xD;
      should also be included&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        It is estimated that approximately 60 patients will be included in the study, 30 newly&#xD;
        diagnosed ITP patients and 30 newly diagnosed MDS cases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged ≥ 18 years old at diagnosis&#xD;
&#xD;
          -  Informed consent in writing&#xD;
&#xD;
          -  Newly diagnosed primary ITP patients, or&#xD;
&#xD;
          -  Newly diagnosed MDS patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who participated in a interventional thrombopoietin receptor agonists&#xD;
             (TPO-RA) clinical trial since TPO-RA treatment initiation&#xD;
&#xD;
          -  Patients with secondary immune thrombopenia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomás González</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Burgos</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Complejo Hospitalario de A Coruña</name>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Burgos</name>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria</name>
      <address>
        <city>Las Palmas De Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Regional de Málaga</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 2, 2018</study_first_submitted>
  <study_first_submitted_qc>March 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

